Answers are grounded in this paper and cite their sources.
The authors advocate against the use of hydroxyethyl starch formulations due to significant safety concerns, challenging the EMA's decision to permit continued use in some patients.
Large trials have shown that hydroxyethyl starch increases the risk of death, kidney injury, and bleeding. However, an EMA review last year permitted continued use in some patients, overturning an earlier decision to withdraw the product completely. Christiane Hartog and colleagues discuss the evidence and call on doctors to avoid using starch formulations
No takes yet. Share an insight, caveat, or question.
Hartog et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: